Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Costs and Expenses:
General and administrative	$ 1,620	$ 2,090
Research and development	3,370	6,059
Total Operating Costs and Expenses	4,990	8,149
Loss from Operations	(4,990)	(8,149)
Other Income:
Change in fair value of warrant liability	2,655	5,090
Interest income	9	1
Total Other Income	2,664	5,091
Net Loss	(2,326)	(3,058)
Net Loss Attributable to Non-controlling Interest	(10)	(212)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(2,316)	(2,846)
Series A Preferred Stock Dividends	(59)	0
Net Loss Attributable to Common Stock Holders	$ (2,375)	$ (2,846)
Net Loss Per Share - Basic and Dilutive	$ (0.02)	$ (0.02)
Weighted average number of shares outstanding during the period - Basic and Dilutive	128,566,883	117,447,260